ArticleEpilepsy & behavior : E&B2021
Effect of the COVID-19 pandemic on drug compliance and stigmatization in patients with epilepsy.
Article in Epilepsy & behavior : E&B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it, 47 citations in OpenAlex.
- Seizure Control in Patients with Epilepsy during the COVID-19 Pandemic: A Systematic Review and Meta-analysis.Internal medicine (Tokyo, Japan) · 2022Pooled it
- Evaluation of COVID-19 fear and sleep quality in individuals with epilepsy: a cross-sectional study.Frontiers in neurology · 2025Article
- Promoting medication compliance in epileptic children: a cross sectional survey.BMC pediatrics · 2024Article
- Patterns and determinants of healthcare utilization and medication use before and during the COVID-19 crisis in Afghanistan, Bangladesh, and India.BMC health services research · 2024Article
- Medication compliance of children with epilepsy: a cross-sectional survey.Italian journal of pediatrics · 2023Article
- Prescription trends of antiseizure medications before and during the COVID-19 pandemic.Frontiers in neurology · 2023Article
- Factors associated with medication interruption among outpatients with severe mental illness exposed to COVID-19.Frontiers in public health · 2023Article
- Depression and sexual functions in epilepsy patients: Comparison before and during the COVID-19 pandemic.Annales medico-psychologiques · 2022Article
- A year with the fear of COVID-19 in multiple sclerosis patients: Examination of depression, sleep quality and quality of life before and after the pandemic.Multiple sclerosis and related disorders · 2022Article
- Effects of the COVID-19 pandemic on medication adherence: In the case of antiseizure medications, A scoping review.Seizure · 2021Article
- Effects of hypertonic alkaline nasal irrigation on COVID-19.Laryngoscope investigative otolaryngology · 2021Article
- Prevalence of depression and suicidal ideation in persons with epilepsy during the COVID-19 pandemic: A longitudinal study from India.Epilepsy & behavior : E&B · 2021Article
- Sexuality and epilepsy in the COVID era: Tips and tricks.Epilepsy & behavior : E&B · 2021Article
- Impact of COVID-19 pandemic on community medication dispensing: a national cohort analysis in Wales, UK.International journal of population data science · 2020Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivePandemics like coronavirus disease 2019 (COVID-19) bring along many individual and social problems. We aimed to investigate what changes the COVID-19 pandemic can cause in patients with epilepsy on drug compliance and stigmatization. MATERIAL AND
methodModified Morisky Scale (MMS) and stigmatization scales were used between October and November 2019 to assess drug compliance and stigmatization in epilepsy patients. These scales were renewed in June and July 2020 in the same patient group to assess the impact of the epidemic on drug compliance and stigmatization in patients with epilepsy. Statistical analysis was performed using the statistical software SPSS 17.0 for Windows (SPSS, Inc). Demographic and clinical characteristics of the patients were recorded in SPSS. The interviews were conducted during the interictal period. Paired-samples t-test was used to compare the stigma scale results of epilepsy patients before and during COVID-19. The Wilcoxon test was used to compare MMS groups before and during COVID-19.
resultsA total of 110 patients were included in the study. There was no significant difference between the pre-pandemic and pandemic period in epilepsy stigma scale used to evaluate stigmatization levels in patients. During the pandemic period, it was observed that patients had higher motivation and higher knowledge than before the pandemic (p = 0.048). There were seven patients (6.4%) whose seizure frequency increased during the pandemic period. There were two patients (1.8%) who had difficulty in accessing drugs during the pandemic period. In multivariate analysis, only parameter that predicted an increase in seizure frequency was the number of drugs used In the of COVID-19 period. In correlation analysis, a negative correlation was found between the stigma total score during COVID-19 period and education level.
conclusionA slight increase in the frequency of seizures was observed in our patients during the pandemic period, and no significant problem was experienced in accessing drugs. The COVID-19 pandemic made patients more motivated and informed in drug compliance in the patient group and had no effect on stigmatization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.